MET Exon 14 Skipping in Non-Small Cell Lung Cancer

被引：88

作者：

Heist, Rebecca S. ^{[1
]}

Shim, Hyo Sup ^{[2
,3
]}

Gingipally, Shalini ^{[1
]}

Mino-Kenudson, Mari ^{[2
]}

Le, Long ^{[2
]}

Gainor, Justin F. ^{[1
]}

Zheng, Zongli ^{[2
]}

Aryee, Martin ^{[2
]}

Xia, Junfeng ^{[4
,5
]}

Jia, Peilin ^{[5
]}

Jin, Hailing ^{[6
]}

Zhao, Zhongming ^{[5
,7
]}

Pao, Gwilliam ^{[6
]}

Engelman, Jeffrey A. ^{[1
]}

Iafrate, A. John ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Med, Canc Ctr, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

[3] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea

[4] Anhui Univ, Inst Hlth Sci, Hefei 230039, Anhui, Peoples R China

[5] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA

[6] Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Med, Nashville, TN 37212 USA

[7] Univ Texas Hlth Sci Ctr Houston, Ctr Precis Hlth, Sch Biomed Informat, Houston, TX 77030 USA

来源：

ONCOLOGIST | 2016年 / 21卷 / 04期

关键词：

Lung cancer; MET exon 14 skipping; Targeted therapy; MUTATIONS; SENSITIVITY; GEFITINIB; GENE; RESPONSIVENESS; INHIBITION; ACTIVATION; CRIZOTINIB; TUMORS;

D O I：

10.1634/theoncologist.2015-0510

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. Non-small cell lung cancers (NSCLCs) harboring specific genetic alterations can be highly sensitive to targeted therapies. Materials and Methods. We performed a targeted rearrangement assay on 54 NSCLCs across all stages that were from patients who were never smokers and did not have driver mutations. Because MET exon 14 skipping was the most frequent alteration found, we surveyed the results for MET exon 14 skipping at Massachusetts General Hospital (MGH) since the inclusion of this alteration into our current molecular profiling panel. Results. In a cohort of 54 never-smokers with lung cancers that were wild-type for known driver mutations, MET exon 14 skipping was the most frequently recurring alteration, occurring in 10 cancers (19%). Clinical testing at MGH via our next-generation sequencing (NGS) and NGS-rearrangement panels showed an additional 16 cases of MET exon 14 skipping, for an overall estimated frequency of 5.6%. A clinical case of a patient with MET exon 14 skipping treated with the MET inhibitor crizotinib is also described. Conclusion. MET exon 14 skipping is a targetable gene alteration found in NSCLC. Patients with these alterations may respond well to MET inhibition.

引用

页码：481 / 486

页数：6

共 27 条

[1]

Awad MM., 2016, J Clin Oncol

[2]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[3] Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine [J].

Dias-Santagata, Dora ;

Akhavanfard, Sara ;

David, Serena S. ;

Vernovsky, Kathy ;

Kuhlmann, Georgiana ;

Boisvert, Susan L. ;

Stubbs, Hannah ;

McDermott, Ultan ;

Settleman, Jeffrey ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Isakoff, Steven J. ;

Sequist, Lecia V. ;

Engelman, Jeffrey A. ;

Lynch, Thomas J. ;

Haber, Daniel A. ;

Louis, David N. ;

Ellisen, Leif W. ;

Borger, Darrell R. ;

Lafrate, A. John .

EMBO MOLECULAR MEDICINE, 2010, 2 (05) :146-158

[4] Somatic mutations affect key pathways in lung adenocarcinoma [J].

Ding, Li ;

Getz, Gad ;

Wheeler, David A. ;

Mardis, Elaine R. ;

McLellan, Michael D. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Greulich, Heidi ;

Muzny, Donna M. ;

Morgan, Margaret B. ;

Fulton, Lucinda ;

Fulton, Robert S. ;

Zhang, Qunyuan ;

Wendl, Michael C. ;

Lawrence, Michael S. ;

Larson, David E. ;

Chen, Ken ;

Dooling, David J. ;

Sabo, Aniko ;

Hawes, Alicia C. ;

Shen, Hua ;

Jhangiani, Shalini N. ;

Lewis, Lora R. ;

Hall, Otis ;

Zhu, Yiming ;

Mathew, Tittu ;

Ren, Yanru ;

Yao, Jiqiang ;

Scherer, Steven E. ;

Clerc, Kerstin ;

Metcalf, Ginger A. ;

Ng, Brian ;

Milosavljevic, Aleksandar ;

Gonzalez-Garay, Manuel L. ;

Osborne, John R. ;

Meyer, Rick ;

Shi, Xiaoqi ;

Tang, Yuzhu ;

Koboldt, Daniel C. ;

Lin, Ling ;

Abbott, Rachel ;

Miner, Tracie L. ;

Pohl, Craig ;

Fewell, Ginger ;

Haipek, Carrie ;

Schmidt, Heather ;

Dunford-Shore, Brian H. ;

Kraja, Aldi ;

Crosby, Seth D. ;

Sawyer, Christopher S. .

NATURE, 2008, 455 (7216) :1069-1075

[5] Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors [J].

Frampton, Garrett M. ;

Ali, Siraj M. ;

Rosenzweig, Mark ;

Chmielecki, Juliann ;

Lu, Xinyuan ;

Bauer, Todd M. ;

Akimov, Mikhail ;

Bufill, Jose A. ;

Lee, Carrie ;

Jentz, David ;

Hoover, Rick ;

Ou, Sai-Hong Ignatius ;

Salgia, Ravi ;

Brennan, Tim ;

Chalmers, Zachary R. ;

Jaeger, Savina ;

Huang, Alan ;

Elvin, Julia A. ;

Erlich, Rachel ;

Fichtenholtz, Alex ;

Gowen, Kyle A. ;

Greenbowe, Joel ;

Johnson, Adrienne ;

Khaira, Depinder ;

McMahon, Caitlin ;

Sanford, Eric M. ;

Roels, Steven ;

White, Jared ;

Greshock, Joel ;

Schlegel, Robert ;

Lipson, Doron ;

Yelensky, Roman ;

Morosini, Deborah ;

Ross, Jeffrey S. ;

Collisson, Eric ;

Peters, Malte ;

Stephens, Philip J. ;

Miller, Vincent A. .

CANCER DISCOVERY, 2015, 5 (08) :850-859

[6] Comprehensive genomic characterization of squamous cell lung cancers [J].

Hammerman, Peter S. ;

Lawrence, Michael S. ;

Voet, Douglas ;

Jing, Rui ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Stojanov, Petar ;

McKenna, Aaron ;

Lander, Eric S. ;

Gabriel, Stacey ;

Getz, Gad ;

Sougnez, Carrie ;

Imielinski, Marcin ;

Helman, Elena ;

Hernandez, Bryan ;

Pho, Nam H. ;

Meyerson, Matthew ;

Chu, Andy ;

Chun, Hye-Jung E. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Sipahimalani, Payal ;

Stoll, Dominik ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron S. N. ;

Chuah, Eric ;

Coope, Robin J. N. ;

Corbett, Richard ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Anhe Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Karen ;

Nip, Ka Ming ;

Olshen, Adam ;

Schein, Jacqueline E. ;

Slobodan, Jared R. ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard ;

Zeng, Thomas ;

Zhao, Yongjun ;

Jones, Steven J. M. .

NATURE, 2012, 489 (7417) :519-525

[7] Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation [J].

Jenkins, Russell W. ;

Oxnard, Geoffrey R. ;

Elkin, Sheryl ;

Sullivan, E. Kelly ;

Carter, Jennifer L. ;

Barbie, David A. .

CLINICAL LUNG CANCER, 2015, 16 (05) :E101-E104

[8] Somatic mutations lead to an oncogenic deletion of Met in lung cancer [J].

Kong-Beltran, M ;

Seshagiri, S ;

Zha, JP ;

Zhu, WJ ;

Bhawe, K ;

Mendoza, N ;

Holcomb, T ;

Pujara, K ;

Stinson, J ;

Fu, L ;

Severin, C ;

Rangell, L ;

Schwall, R ;

Amler, L ;

Wickramasinghe, D ;

Yauch, R .

CANCER RESEARCH, 2006, 66 (01) :283-289

[9] Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer [J].

Kwak, Eunice L. ;

Bang, Yung-Jue ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Solomon, Benjamin ;

Maki, Robert G. ;

Ou, Sai-Hong I. ;

Dezube, Bruce J. ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Varella-Garcia, Marileila ;

Kim, Woo-Ho ;

Lynch, Thomas J. ;

Fidias, Panos ;

Stubbs, Hannah ;

Engelman, Jeffrey A. ;

Sequist, Lecia V. ;

Tan, WeiWei ;

Gandhi, Leena ;

Mino-Kenudson, Mari ;

Wei, Greg C. ;

Shreeve, S. Martin ;

Ratain, Mark J. ;

Settleman, Jeffrey ;

Christensen, James G. ;

Haber, Daniel A. ;

Wilner, Keith ;

Salgia, Ravi ;

Shapiro, Geoffrey I. ;

Clark, Jeffrey W. ;

Iafrate, A. John .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1693-1703

[10] Effects of IGF2BP2, KCNQ1, and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen [J].

Liu, Xin ;

Chen, Zhiyu ;

Zhao, Xiaoying ;

Huang, Mingzhu ;

Wang, Chenchen ;

Peng, Wei ;

Yin, Ji Liang ;

Li, Jin ;

He, Guang ;

Li, Xin ;

Zhu, Xiaodong .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

← 1 2 3 →